- Home
- GOF vs CPRX Comparison
GOF vs CPRX Comparison
Compare GOF & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOF
- CPRX
- Stock Information
- Founded
- GOF 2006
- CPRX 2002
- Country
- GOF United States
- CPRX United States
- Employees
- GOF N/A
- CPRX N/A
- Industry
- GOF Finance/Investors Services
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- GOF Finance
- CPRX Health Care
- Exchange
- GOF Nasdaq
- CPRX Nasdaq
- Market Cap
- GOF 2.4B
- CPRX 2.9B
- IPO Year
- GOF N/A
- CPRX 2006
- Fundamental
- Price
- GOF $14.78
- CPRX $24.90
- Analyst Decision
- GOF
- CPRX Strong Buy
- Analyst Count
- GOF 0
- CPRX 7
- Target Price
- GOF N/A
- CPRX $32.29
- AVG Volume (30 Days)
- GOF 789.2K
- CPRX 1.1M
- Earning Date
- GOF 01-01-0001
- CPRX 05-07-2025
- Dividend Yield
- GOF 15.42%
- CPRX N/A
- EPS Growth
- GOF N/A
- CPRX 178.13
- EPS
- GOF N/A
- CPRX 1.57
- Revenue
- GOF N/A
- CPRX $534,645,999.00
- Revenue This Year
- GOF N/A
- CPRX $16.37
- Revenue Next Year
- GOF N/A
- CPRX $8.80
- P/E Ratio
- GOF N/A
- CPRX $15.85
- Revenue Growth
- GOF N/A
- CPRX 29.97
- 52 Week Low
- GOF $10.96
- CPRX $14.75
- 52 Week High
- GOF $16.76
- CPRX $26.16
- Technical
- Relative Strength Index (RSI)
- GOF 56.11
- CPRX 58.78
- Support Level
- GOF $14.29
- CPRX $24.19
- Resistance Level
- GOF $14.89
- CPRX $25.00
- Average True Range (ATR)
- GOF 0.14
- CPRX 0.72
- MACD
- GOF 0.03
- CPRX 0.05
- Stochastic Oscillator
- GOF 81.67
- CPRX 78.41
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).